



Attorney Docket No. 70207-56,879

7614
LB
8/23/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peter C. Meltzer, et al.

RECEIVED

U.S.S.N. 10/033,621

Art Unit: 1614

JUL 10 2002

FILED: December 27, 2001

Examiner: Not Yet Assigned

TECH CENTER 1600/2900

FOR: TROPANE ANALOGS AND METHODS FOR INHIBITION OF MONOAMINE TRANSPORT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, Postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on July 3, 2002.

By: Susan Miller

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)

Commissioner for Patents
Washington, D.C. 20231

Date July 3, 2002

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

RECEIVED
JUL 11 2002
TECH CENTER 1600/2900

RECEIVED

II. COPIES

- a. Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.

- b. within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. No certification; therefore, a fee in the amount of \$_____ is required by 37 C.F.R. . § 1.17(p).
or
- b. See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- Please charge Deposit Account No. 04-1105 in the amount of \$_____ for the above-indicated fee. A triplicate copy of this paper is attached.
- No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,

Date: July 3, 2002



Edward J. Adamson (Reg. No. 50,927
DIKE, BRONSTEIN, ROBERTS & CUSHMAN
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444



RECEIVED

JUL 10 2002

Sheet 1 of 1

TECH CENTER 1600/2900

| | | | |
|---|--|------------------------------------|--------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | ATTY DOCKET NO. 70207-56,579 | SERIAL NO. 10/033,621 |
| | | APPLICANT Peter C. Meltzer, et al. | |
| | | FILING DATE: 12/27/2001 | ART UNIT: 1614 |

UNITED STATES PATENT DOCUMENTS

| EXAM. INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FIL. DATE IF APPR |
|------------------|----|--------------------|------------|-----------------------|-------|--------------|-------------------------|
| | AA | 4,434,151 | 02/28/1984 | Byrne, et al. | | | 11/08/1982 |
| | AB | 4,673,562 | 06/16/1987 | Davison, et al | | | 08/19/1983 |
| | AC | 4,746,505 | 05/24/1988 | Jones et al. | | | 04/26/1985 |
| | AD | 5,426,189 | 06/20/1995 | Kung et al. | | | 05/24/1994 |
| | AE | 5,334,728 | 08/02/1994 | Kung et al. | | | 10/06/1992 |
| | AF | 5,122,361 | 06/16/1992 | Kung et al. | | | 04/17/1989 |
| | AG | 5,128,118 | 07/07/1992 | Carroll et al. | | | 08/09/1990 |
| . | AH | 5,413,779 | 05/09/1995 | Kuhar et al. | | | 08/09/1991 |
| | AI | 5,439,666 | 08/08/1995 | Neumeyer et al. | | | 11/24/1994 |
| | AJ | 5,310,912 | 05/10/1994 | Neumeyer et al. | | | 02/25/1992 |
| | AK | 5,128,118 | 07/07/1992 | Carroll et al. | | | 08/09/1990 |
| | AL | 5,380,848 | 01/10/1995 | Kuhar et al. | | | 04/26/1994 |
| | AM | 5,980,860 | 11/09/1999 | Kung et al. | | | 07/16/1998 |
| | AN | 5,493,026 | 02/20/1996 | Elmaleh et al. | | | 10/25/1993 |
| | AO | 3,813,404 | 05/28/1974 | Clark, et al. | | | 11/15/1972 |
| | AP | 4,499,099 | 02/12/1985 | Watts | | | 06/09/1982 |
| | AQ | 6,350,758,B1 | 02/26/2002 | Kozikowski, et al. | | | 12/02/1997 |

RECEIVED
JUL 11 2002

TECH CENTER 1600/2900

| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTY DOCKET NO. 70207-56,579 | SERIAL NO. 10/033,621 | | |
|---|----|---|------------|------------------------------------|--------------------------|-----------|-------------|
| | | | | APPLICANT Peter C. Meltzer, et al. | | | |
| | | | | FILING DATE: 12/27/2001 | ART UNIT: 1614 | | |
| UNITED STATES PATENT DOCUMENTS | | | | | | | |
| RECEIVED JUL 10 2002 | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| TECH CENTER 1600/2900 | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | TRAN YES/NO |
| | BA | WO 97/14445 | 04/24/1997 | PCT | | | YES |
| | BB | WO 95/11901 | 05/04/1995 | PCT | | | Yes |
| | BC | WO 93/09814 | 05/27/1993 | PCT | | | Yes |
| | BD | EP 0 135 160 A2 | 03/27/1985 | EPO | | | Yes |
| | BE | WO 98/24788 | 06/11/1998 | PCT | | | Yes |
| | BF | GB 2349882 A | 11/15/2000 | PCT | | | Yes |
| | BG | WO 97/16210 | 05/09/1997 | PCT | | | Yes |
| | BH | WO 97/47328 | 12/18/1997 | PCT | | | Yes |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | | | | | | | |
| | CA | Brandau, et al., <i>Nucl. Med. Biol.</i> (1994) Vol. 21, No. 8, pp.1073-1081 | | | | | |
| | CB | Bryson, et al., <i>Inorg. Chem.</i> (1988), 27, pp. 2154-2161 | | | | | |
| | CC | Davison, et al., <i>Inorg. Chem.</i> (1981) Vol. 20, No. 6, pp. 1629-1632 | | | | | |
| | CD | DiZio, et al., <i>Bioconjugate Chemistry</i> , (1991) Vol. 2, No. 5, pp.353-366 | | | | | |
| | CE | DiZio, et al., <i>Journal of Nuclear Medicine</i> (1992) Vol. 33, No. 4, pp. 558-569 | | | | | |
| | CF | Fritzberg, et al., <i>J. Nucl. Med.</i> (1981) Vol. 22, No.3, pp. 258-263 | | | | | |
| | CG | Fritzberg, et al., <i>J. Nucl. Med.</i> (1982) Vol. 23, No. 7, pp. 592-598 | | | | | |
| | CH | Gustavson, et al., NeoRx Corp, Seattle, WA 98119, pp. 5485-5488 | | | | | |
| | CI | Hansen, et al., <i>J. Nuc. Med.</i> (1994) Vol. 35, No. 7, pp. 1198-1205 | | | | | |
| | CJ | Jones, et al., <i>J. Nucl. Med.</i> (1982) Vol. 23, No. 9, pp. 801-809 | | | | | |
| | CK | Steigman, et al., <i>National Academy Press NAS-NS-3204</i> Prepared for the Committee on Nuclear and Radiochemistry, National Research Council (1992) pp.117-127 | | | | | |

| | | | | | | | |
|---|-----|---|-------------------------|------------------------------------|----------------------------|-----------------------|-------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | TECH CENTER 1600/2900 | RECEIVED JUL 11 2002 | PATTY DOCKET NO. 70207-56,579 | SERIAL NO. 10/033,621 | TECH CENTER 1600/2900 | RECEIVED JUL 10 2002 |
| | | | | APPLICANT Peter C. Meltzer, et al. | FILING DATE: 12/27/2001 | ART UNIT: 1614 | |
| UNITED STATES PATENT DOCUMENTS | | | | | | | |
| | CL | Archer, et al., University of Essex, Colchester, England, pp.177-179 | | | | | |
| | CM | Baldwin, et al., Yale Univ. School of Med., Westhaven, CT, pp. 329-332 | | | | | |
| | CN | Kelly, et al., Amersham Int., Amersham, Bucks, UK, pp. 259-263 | | | | | |
| | CO | Kung, et al., Univ. of PA, Philadelphia, PA, pp. 293-298 | | | | | |
| . | CP | Liu et al., The DuPont Merck Pharm. Co. N. Billerica, MA, pp. 383-393 | | | | | |
| | CQ | Mahmood, et al., Harvard Medical School, Boston, MA, pp. 211-215 | | | | | |
| | CR | Volkert, Univ. of Missouri Columbia, MO, pp. 17-26 | | | | | |
| | CS | Davies, et al, <i>J. Med. Chem.</i> , (1994) Vol. 37, No. 9, pp. 1262-1268 | | | | | |
| | CT | Bennett, et al., <i>J. of Pharmacology</i> (1995) Vol. 272, No. 3, pp. 1176-1186 | | | | | |
| | CU | Rao, et al, Eighth International Symposium on Radiopharmaceutical Chemistry, Princeton Univ. (1990) pp. 39-40 | | | | | |
| . | CV | <i>Johannsen, et al., Eleventh Intern. Symposium Radiopharmaceutical Chem. Abstracts</i> (1995), pp. 319-320 | | | | | |
| . | CW | Agoston, et al., <i>Amer. Chem. Society</i> , (1997) Vol. 40, No. 26, pp. 4329-4339 | | | | | |
| | CX | Carroll, et al., <i>J. Med. Chem.</i> (1993) Vol. 36, No. 20, pp. 2886-2890 | | | | | |
| | CY | Casy, et al., <i>J. Pharm. Pharmacol.</i> (1992) Vol. 44, pp. 787-790 | | | | | |
| | CZ | Daum, et al., <i>J. Med. Chem.</i> (1975), Vol. 18, No. 5, pp. 496-501 | | | | | |
| | CAA | Holmquist, et al., <i>J. Med. Chem.</i> (1996), Vol. 39, No. 21, pp. 4139-4141 | | | | | |
| | CAB | Meegalla, et al., <i>J. Am. Chem. Soc.</i> (1995) Vol. 117, No. 44, pp. 11037-11038 | | | | | |
| | CAC | Meegalla, et al., <i>J. Am. Chem. Soc.</i> (1996) Vol. 7, No. 4, pp. 421-429 | | | | | |
| | CAD | Clarke, et al., <i>J. Med. Chem.</i> (1973) Vol. 16, No. 11, pp. 1260-1267 | | | | | |
| | CAE | Ohmomo, et al., <i>J. Med. Chem.</i> (1992) Vol. 35, No. 1, pp. 157-162 | | | | | |
| | CAF | Carroll, et al., <i>J. Med. Chem.</i> (1995) Vol. 38, No. 2, pp. 379-388 | | | | | |
| | CAG | Kline, et al., <i>J. Med. Chem.</i> (1997) Vol. 40, No. 6, pp. 851-857 | | | | | |
| | CAH | Meltzer, et al., <i>J. Med. Chem.</i> (1996) Vol. 39, No. 2, pp. 371-379 | | | | | |
| | CAI | Meltzer, et al., <i>J. Med. Chem.</i> (1997) Vol. 40, No. 17, pp. 2661-2673 | | | | | |

| | | | | | |
|---|---|-----------------------|-------------------------|------------------------------------|--|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | TECH CENTER 1600/2900 | RECEIVED JUL 11 2002 | ATTY DOCKET NO. 70207-56,579 | SERIAL NO. 10/033,621 |
| | | | | APPLICANT Peter C. Meltzer, et al. | JUL 10 2002 TECH CENTER 1600/2900 RECEIVED |
| | | | | FILING DATE: 12/27/2001 | ART UNIT: 1614 |
| UNITED STATES PATENT DOCUMENTS | | | | | |
| CAJ | Meltzer, et al., <i>J. Med. Chem.</i> (1994) Vol. 37, No. 13, pp. 2001-2010 | | | | |
| CAK | Newman, et al., <i>J. Med. Chem.</i> (1999) Vol. 42, No. 18, pp. 3502-3509 | | | | |
| CAL | Newman, et al., <i>J. Med. Chem.</i> (1995) Vol. 38, No. 20, pp. 3933-3940 | | | | |
| CAM | Newman, et al., <i>Current Medicinal Chem.</i> (1998) Vol. 5, No. 4, pp. 305-319 | | | | |
| CAN | Newman, et al., <i>J. Med. Chem.</i> (1994) Vol. 37, No. 15, pp. 2258-2261 | | | | |
| CAO | Riley et al., <i>J. Med. Chem.</i> (1979) pp. 1167-1171 | | | | |
| CAP | Van Eeken, et al., <i>Arch. Int. Pharmacodyn (Netherlands)</i> (1966) Vol. 22, No. 10, Vol. 159, No. 1, pp. 240-249 | | | | |
| CAQ | Cesati, et al., <i>J. Labelled Cpd. Radiopharm.</i> (1999) Vol. 42, Suppl. j, pp. S150-S152 | | | | |
| CAR | Fang, et al., <i>J. Labelled Cpd. Radiopharm.</i> (1999) Vol 42, Suppl. i, pp. S336-S338 | | | | |
| CAS | Hoepping, et al., <i>Universitat Marburg, Pachbereich Kemchemie,</i> (1997) pp. 33-36 | | | | |
| CAT | Hoepping, et al., <i>Bioorganic & Medicinal Chem.</i> (1998) Vol. 6, pp. 1663-1672 | | | | |
| CAU | Hoepping, et al., <i>Bioorganic & Medicinal Chem.</i> (1996) Vol. 6, No. 23, pp. 2871-2874 | | | | |
| CAV | Hoepping, et al., <i>J. Med. Chem.</i> (1998) Vol 41, No. 23, pp. 4429-4432 | | | | |
| CAW | Madras, et al., <i>Synapse</i> (1996) Vol. 22, pp. 239-246 | | | | |
| CAX | Meegalla, et al., <i>J. Med. Chem.</i> (1997) Vol. 40, No. 1, pp. 9-17 | | | | |
| CAY | Meltzer, et al., <i>J. Med. Chem.</i> (1997) Vol. 40, No. 12, pp. 1835-1844 | | | | |
| CAZ | Meltzer, et al., <i>J. Med. Chem.</i> (1993) Vol. 36, No. 7 pp. 855-862 | | | | |
| CBA | Meltzer, et al., <i>Med. Chem. Research</i> (1998) pp. 12-34 | | | | |
| CBB | Meegalla, et al., <i>Bioconjugate Chem.</i> (1996) Vol. 7, No. 4, pp. 421-429 | | | | |
| CBC | Fischman, et al., <i>J. Nuclear Med.</i> (1999) Vol. 40, No. 5 Supplement, p. 262P | | | | |
| CBD | Mozley, et al., <i>J. Nuclear Med.</i> (1995) Vol. 36, No. 5, p. 32P | | | | |
| CBE | Myers, et al., <i>J. Nuclear Med.</i> (1995) Vol. 36, No. 5, p. 124P | | | | |



| | | | |
|---|-------|------------------------------------|--------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | ATTY DOCKET NO. 70207-56,579 | SERIAL NO. 10/033,621 |
| | | APPLICANT Peter C. Meltzer, et al. | |
| | | FILING DATE: 12/27/2001 | ART UNIT: 1614 |
| UNITED STATES PATENT DOCUMENTS | | | |
| Examiner: | Date: | | |
| | | | |

RECEIVED

JUL 10 2002

TECH CENTER 1600/2900

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900